LANTERN PHARMA INC (LTRN) Fundamental Analysis & Valuation

NASDAQ:LTRN • US51654W1018

Current stock price

2.76 USD
+0.27 (+10.84%)
At close:
2.76 USD
0 (0%)
After Hours:

This LTRN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. LTRN Profitability Analysis

1.1 Basic Checks

  • LTRN had negative earnings in the past year.
  • In the past year LTRN has reported a negative cash flow from operations.
  • LTRN had negative earnings in each of the past 5 years.
  • In the past 5 years LTRN always reported negative operating cash flow.
LTRN Yearly Net Income VS EBIT VS OCF VS FCFLTRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -138.85%, LTRN is doing worse than 82.17% of the companies in the same industry.
  • LTRN has a Return On Equity of -197.36%. This is in the lower half of the industry: LTRN underperforms 69.57% of its industry peers.
Industry RankSector Rank
ROA -138.85%
ROE -197.36%
ROIC N/A
ROA(3y)-47.36%
ROA(5y)-37.56%
ROE(3y)-54.18%
ROE(5y)-41.96%
ROIC(3y)N/A
ROIC(5y)N/A
LTRN Yearly ROA, ROE, ROICLTRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800

1.3 Margins

  • LTRN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LTRN Yearly Profit, Operating, Gross MarginsLTRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. LTRN Health Analysis

2.1 Basic Checks

  • There is no outstanding debt for LTRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LTRN Yearly Shares OutstandingLTRN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
LTRN Yearly Total Debt VS Total AssetsLTRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -8.93, we must say that LTRN is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -8.93, LTRN is doing worse than 72.67% of the companies in the same industry.
  • LTRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.93
ROIC/WACCN/A
WACCN/A
LTRN Yearly LT Debt VS Equity VS FCFLTRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

  • LTRN has a Current Ratio of 3.33. This indicates that LTRN is financially healthy and has no problem in meeting its short term obligations.
  • LTRN has a Current ratio (3.33) which is in line with its industry peers.
  • A Quick Ratio of 3.33 indicates that LTRN has no problem at all paying its short term obligations.
  • The Quick ratio of LTRN (3.33) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.33
Quick Ratio 3.33
LTRN Yearly Current Assets VS Current LiabilitesLTRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. LTRN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 18.65% over the past year.
EPS 1Y (TTM)18.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • LTRN is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -9.11% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-24.09%
EPS Next 2Y-14.56%
EPS Next 3Y-11.09%
EPS Next 5Y-9.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LTRN Yearly Revenue VS EstimatesLTRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 20M 40M 60M
LTRN Yearly EPS VS EstimatesLTRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. LTRN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LTRN. In the last year negative earnings were reported.
  • Also next year LTRN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LTRN Price Earnings VS Forward Price EarningsLTRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LTRN Per share dataLTRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

  • A cheap valuation may be justified as LTRN's earnings are expected to decrease with -11.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.56%
EPS Next 3Y-11.09%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LTRN Dividend Analysis

5.1 Amount

  • LTRN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LTRN Fundamentals: All Metrics, Ratios and Statistics

LANTERN PHARMA INC

NASDAQ:LTRN (4/20/2026, 4:30:38 PM)

After market: 2.76 0 (0%)

2.76

+0.27 (+10.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-30
Earnings (Next)05-05
Inst Owners19.84%
Inst Owner Change0%
Ins Owners0.41%
Ins Owner Change0%
Market Cap31.05M
Revenue(TTM)N/A
Net Income(TTM)-18.92M
Analysts82.86
Price Target25.5 (823.91%)
Short Float %22.46%
Short Ratio3.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.9%
Min EPS beat(2)18.65%
Max EPS beat(2)19.14%
EPS beat(4)3
Avg EPS beat(4)12.49%
Min EPS beat(4)-3.81%
Max EPS beat(4)19.14%
EPS beat(8)6
Avg EPS beat(8)10.32%
EPS beat(12)10
Avg EPS beat(12)15.19%
EPS beat(16)13
Avg EPS beat(16)15.99%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)25%
PT rev (3m)25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.24
P/tB 3.24
EV/EBITDA N/A
EPS(TTM)-1.57
EYN/A
EPS(NY)-1.95
Fwd EYN/A
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.5
OCFYN/A
SpS0
BVpS0.85
TBVpS0.85
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -138.85%
ROE -197.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.36%
ROA(5y)-37.56%
ROE(3y)-54.18%
ROE(5y)-41.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.97%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.33
Quick Ratio 3.33
Altman-Z -8.93
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)166.97%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y-24.09%
EPS Next 2Y-14.56%
EPS Next 3Y-11.09%
EPS Next 5Y-9.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-96.32%
EBIT Next 3Y-41.56%
EBIT Next 5Y-25.19%
FCF growth 1Y-23.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.67%
OCF growth 3YN/A
OCF growth 5YN/A

LANTERN PHARMA INC / LTRN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for LANTERN PHARMA INC?

ChartMill assigns a fundamental rating of 2 / 10 to LTRN.


What is the valuation status for LTRN stock?

ChartMill assigns a valuation rating of 0 / 10 to LANTERN PHARMA INC (LTRN). This can be considered as Overvalued.


Can you provide the profitability details for LANTERN PHARMA INC?

LANTERN PHARMA INC (LTRN) has a profitability rating of 0 / 10.